CME

Faculty: J.A. Randy Englert, MD, FACC This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustain...

Faculty: Erica L. Mayer, MD, MPH Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing...

Faculty: Aditya Bardia, MD, MPH, FASCO Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optim...

Faculty: Aditya Bardia, MD, MPH, FASCO Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optim...

Faculty: Maria Fleseriu, MD, FACE Faculty: Shlomo Melmed, MBChB Faculty: Elise M. Brett, MD, FACE This broadcast replay from AACE 2026 features an interactive, case-based Q-Challenge format focused on acromegaly. Participants engage with clinical scenarios designed to assess and reinforce diagnostic evaluation and treatment decision-making. The activity highlights key considerations in identifying...

Host: Brett Bade, MD Guest: Michael Gieske, MD This episode focuses on improving lung cancer screening and early detection by helping primary care providers recognize eligible and high-risk patients, apply current screening guidelines, and engage patients in clear shared decision-making conversations. Speakers will explore why many patients who qualify for low-dose CT scan screening are still not...

Faculty: Michael Dolinger, MD, MBA Faculty: David T. Rubin, MD This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-...

Faculty: Michael Dolinger, MD, MBA Faculty: David T. Rubin, MD This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-...

Faculty: Michael Dolinger, MD, MBA Faculty: David T. Rubin, MD This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-...

Faculty: Michael Dolinger, MD, MBA Faculty: Florence Odufalu, MD This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective ant...

Faculty: Ugo Iroku, MD, MHS Faculty: Michael Dolinger, MD, MBA This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-...

Faculty: Florence Odufalu, MD Faculty: Ugo Iroku, MD, MHS Faculty: Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover convention...

Faculty: Florence Odufalu, MD Faculty: Ugo Iroku, MD, MHS This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integ...

Faculty: Kathleen N. Moore, MD, MS Dr. Kathleen Moore reviews the clinical significance of HER2 expression across diverse solid tumors and its role in guiding treatment decisions. She outlines HER2 testing methodologies, including immunohistochemistry (IHC), to identify patients with advanced solid tumors who may benefit from HER2-targeted antibody–drug conjugates (ADCs). Dr. Moore summarizes key...

Faculty: Jean Hoffman-Censits, MD This 15-minute online CME activity reviews the clinical implications of the updated NCCN Guidelines for advanced urothelial carcinoma (aUC), with a focus on evolving first-line and subsequent treatment strategies. The program highlights the shift away from cisplatin eligibility as the primary determinant of frontline therapy selection and examines key clinical tri...

Faculty: Adam J. Luginbuhl, MD Faculty: Jennifer Johnson, MD, PhD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, r...

Faculty: Jennifer Johnson, MD, PhD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitne...

Faculty: Jennifer Johnson, MD, PhD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitne...

Faculty: Adam J. Luginbuhl, MD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness f...

Faculty: Adam J. Luginbuhl, MD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness f...

Faculty: Honey East, MD Faculty: Amir H. Hamrahian, MD Faculty: Rosario Pivonello, MD, PhD This webinar aims to give learners a case-based exploration of hypercortisolism/Cushing Syndrome (CS) care, covering screening, diagnosis, referral, and treatment. It will closely examine how to identify and screen for atypical presentations of CS, as well as approaches to managing mild cases. The program wi...

Faculty: Hanford Yau, MD, CCD, FACP, FACE Faculty: Eden Miller, DO With an updated understanding of how common hypercortisolism is among patients with hard-to-manage cardiometabolic conditions, what are the implications for clinical practice? How can healthcare providers determine who should be screened, carry out straightforward screening, and confirm a diagnosis? And once hypercortisolism is ide...

Faculty: Neeraj Agarwal, MD, FASCO Faculty: Rana McKay, MD Drs. Neeraj Agarwal and Rana McKay discuss treatment intensification strategies in metastatic castration-sensitive prostate cancer (mCSPC), with a focus on combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs) and chemotherapy. They review key clinical trial data supporting doublet and triplet regim...

Faculty: Anthony Fernandez, MD, PhD Generalized pustular psoriasis (GPP) can look familiar but missing it can have serious consequences. Uncover how IL-36 signaling and immune dysregulation shape disease presentation, progression, and treatment response. You’ll learn to distinguish GPP from other neutrophilic dermatoses using clinical clues, biomarkers, and diagnostic tools. Explore how emerging t...

Faculty: Patrick Rossignol, MD, PhD Faculty: Julio Núñez, MD, PhD Iron deficiency and iron-deficiency anemia are related but distinct clinical entities, with iron deficiency often preceding or occurring independently of anemia. In chronic kidney disease (CKD), inflammation-driven iron sequestration and impaired iron availability frequently develop before hemoglobin declines, making hemoglobin-only...